W. Smith

发表

Effects of rolipram on responses to acute and chronic antigen exposure in monkeys.

C. Andresen, W. Smith, C. Turner, 1994, American journal of respiratory and critical care medicine.

Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study

E. Ravussin, S. Klein, C. Ukomadu, 2022, Nature Network Boston.

Acute Hemodynamic and Clinical Effects of Levosimendan in Patients With Severe Heart Failure

S. Gottlieb, T. LeJemtel, B. Greenberg, 2000, Circulation.

Acute Hemodynamic Effects of Conivaptan, a Dual V1A and V2 Vasopressin Receptor Antagonist, in Patients With Advanced Heart Failure

J. Ghali, M. Pressler, M. Konstam, 2001 .

Pharmacokinetics of Laropiprant and Glucuronide Metabolite in Patients with Severe Renal Insufficiency

J. Wagner, J. Stone, M. Stroh, 2009, American journal of therapeutics.

Pharmacokinetics, pharmacodynamics, and safety of clevidipine after prolonged continuous infusion in subjects with mild to moderate essential hypertension

D. Mould, T. Marbury, William B. Smith, 2012, European Journal of Clinical Pharmacology.

Safety and Pharmacokinetics of Taniborbactam (VNRX-5133) with Cefepime in Subjects with Various Degrees of Renal Impairment

T. Marbury, T. Henkel, William B. Smith, 2022, Antimicrobial agents and chemotherapy.

Continued efficacy and safety of flibanserin in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD): results from a randomized withdrawal trial.

M. Sand, William B. Smith, J. Kaufman, 2011, The journal of sexual medicine.

Acute Hemodynamic Effects of Conivaptan , a Dual V 1 A and V 2 Vasopressin Receptor Antagonist , in Patients With Advanced Heart Failure

J. Ghali, M. Pressler, M. Konstam, 2001 .

Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.

J. Ouyang, C. Orlandi, J. Burnett, 2006, American journal of physiology. Renal physiology.

Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Verinurad, a Selective Uric Acid Reabsorption Inhibitor

Caroline A. Lee, T. Marbury, Zancong Shen, 2018, Clinical Drug Investigation.

Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure

D. Brater, William B. Smith, P. Black, 1995, Clinical pharmacology and therapeutics.

Short course of systemic corticosteroids in sinonasal polyposis: A double‐blind, randomized, placebo‐controlled trial with evaluation of outcome measures

M. Vadas, P. Hissaria, D. Gillis, 2006, The Journal of allergy and clinical immunology.

Blood Pressure Lowering Effects of a New Long-Acting Inhibitor of Phosphodiesterase 5 in Patients With Mild to Moderate Hypertension

D. Xuan, M. Pressler, J. Mancuso, 2009, Hypertension.

Safety and Pharmacokinetic Profiles of Phosphorodiamidate Morpholino Oligomers with Activity against Ebola Virus and Marburg Virus: Results of Two Single-Ascending-Dose Studies

P. Iversen, P. Sazani, E. Kaye, 2014, Antimicrobial Agents and Chemotherapy.

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.

G. Yancopoulos, N. Stahl, E. Stein, 2012, The New England journal of medicine.

Valsartan plus hydrochlorothiazide: a review of its use since its introduction

Jujhar Bains, William B. Smith, W. Smith, 2011, Expert opinion on pharmacotherapy.

Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer’s disease

G. Kerchner, K. Scearce-Levie, I. Hötzel, 2021, Science Translational Medicine.

Effect of raxibacumab on immunogenicity of Anthrax Vaccine Adsorbed: a phase 4, open-label, parallel-group, randomised non-inferiority study.

J. Billiard, O. Della Pasqua, L. Tan, 2020, The Lancet. Infectious diseases.

Randomized, Controlled Trial of a 13-Valent Pneumococcal Conjugate Vaccine Administered Concomitantly with an Influenza Vaccine in Healthy Adults

E. Emini, A. Gurtman, R. Frenck, 2012, Clinical and Vaccine Immunology.

Clinical benefit of midodrine hydrochloride in symptomatic orthostatic hypotension: a phase 4, double-blind, placebo-controlled, randomized, tilt-table study

Patrick Martin, William B. Smith, H. Wan, 2016, Clinical Autonomic Research.

Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment

M. Palmisano, K. Ogasawara, Christine R. Xu, 2020, Cancer Chemotherapy and Pharmacology.

Effect of food on the bioavailability and tolerability of the JAK2‐selective inhibitor fedratinib (SAR302503): Results from two phase I studies in healthy volunteers

E. Shamiyeh, L. V. von Moltke, Christine R. Xu, 2015, Clinical pharmacology in drug development.

A randomized, placebo-controlled trial of canakinumab in patients with peripheral artery disease

C. Kramer, C. Basson, Timothy Clough, 2019, Vascular medicine.

Phosphodiesterase-5 Blood Pressure Lowering Effects of a New Long-Acting Inhibitor of Phosphodiesterase 5 in Patients With Mild to Moderate Hypertension

D. Xuan, M. Pressler, J. Mancuso, 2009 .

Omapatrilat Versus Lisinopril: Efficacy and Neurohormonal Profile in Salt-Sensitive Hypertensive Patients

V. Campese, K. Lasseter, C. Ferrario, 2001, Hypertension.

Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial.

B. Chaitman, U. Thadani, N. Bittar, 2005, Journal of the American College of Cardiology.

The dynamics of the metabolism of acetate and bicarbonate associated with use of hemodialysates in the ABChD trial: a phase IV, prospective, single center, single blind, randomized, cross-over, two week investigation

R. Thadhani, L. Usvyat, William B. Smith, 2017, BMC Nephrology.

Pharmacokinetics of Micafungin in Healthy Volunteers, Volunteers With Moderate Liver Disease, and Volunteers With Renal Dysfunction

S. Swan, M. Hebert, I. Bekersky, 2005, Journal of clinical pharmacology.

Safety and Pharmacokinetic Profiles of Phosphorodiamidate Morpholino Oligomers with Activity against Ebola Virus and Marburg Virus: Results of Two Single-Ascending-Dose Studies

P. Iversen, P. Sazani, E. Kaye, 2014, Antimicrobial Agents and Chemotherapy.

A phase 1-2 dose-escalating study evaluating the safety and tolerability of istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure with reduced systolic function.

M. Gheorghiade, J. Ghali, A. Amato, 2007, The American journal of cardiology.

A randomized, placebo‐controlled study of the pharmacokinetics, pharmacodynamics, and tolerability of the oral JAK2 inhibitor fedratinib (SAR302503) in healthy volunteers

E. Shamiyeh, L. V. von Moltke, Christine R. Xu, 2014, Journal of clinical pharmacology.

A randomized study of the efficacy and safety of intravenous acetaminophen compared to oral acetaminophen for the treatment of fever.

M. Royal, W. Peacock, William B. Smith, 2011, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial of Four Doses of Tasosartan in Patients With Essential Hypertension

L. Svetkey, J. Pool, Y. Lacourciére, 1998 .

Pharmacokinetics and safety of binodenoson after intravenous dose escalation in healthy volunteers

James R. Johnson, William B. Smith, M. Lamson, 2005, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

Pharmacokinetics, Pharmacodynamics, and Safety of Peginterferon Beta-Ia in Subjects with Normal or Impaired Renal Function

I. Nestorov, T. Marbury, A. Seddighzadeh, 2014, Journal of clinical pharmacology.

The pharmacokinetics of PF-734200, a DPP-IV inhibitor, in subjects with renal insufficiency.

R. Boyd, T. Marbury, S. Terra, 2011, British Journal of Clinical Pharmacology.